Why the study?
Treatments preventing progressive cardiac dysfunction after myocardial infarction are needed, and culture expansion before MSC transplantation hinders homing and reparative abilities.
Does pharmacological mobilisation of mesenchymal stem/stromal cells using mirabegron and AMD3100 improve cardiac function in male Lewis rats post myocardial infarction?
Does pharmacological mobilisation of mesenchymal stem/stromal cells using mirabegron and AMD3100 improve cardiac function in male Lewis rats post myocardial infarction?
Pharmacological mobilisation of endogenous mesenchymal stem/stromal cells using mirabegron and AMD3100 improves cardiac function and reduces fibrosis post myocardial infarction in a rat model.
No takes yet. Share an insight, caveat, or question.
Endogenous MSC mobilization at day 5 post-MI is hypothesis-generating; leaves open whether timed pharmacological strategies enhance cardiac repair.
Todorova et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: